Samrotamab vedotin

N/A

Report date: 2024/03/26 20:00:33

Base Information

Drug NameSamrotamab vedotin

Drug Alias NameABBV-085PR-1498487-MMAE

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsLeucine-rich repeat-containing protein 15 inhibitors

TargetsLeucine-rich repeat-containing protein 15Tubulin

Therapy Area/IndicationsSolid tumoursBreast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesFranceSpain

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsSolid tumoursBreast NeoplasmsSquamous Cell Carcinoma of Head and Neck +[4]

Other Information

ATC CodeN/A